Dear Sir:

This is in reference to your abbreviated new drug application (ANDA), submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), for Memantine and Donepezil Hydrochlorides Extended-Release Capsules, 14 mg/10 mg, and 28 mg/10 mg.

Reference is made to the complete response letter issued by this Office on November 3, 2016, and to your amendments dated November 4, and December 23, 2016. Your November 4, 2016 submission constituted a complete response to our November 3, 2016 action letter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter.

The Office of Bioequivalence has determined your Memantine and Donepezil Hydrochloride Extended-Release Capsules, 14 mg/10 mg and 28 mg/10 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Namzaric Extended-Release Capsules, 14 mg/10 mg and 28 mg/10 mg of Forest Laboratories LLC (Forest).

Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA. The “interim” dissolution specifications are as follows:

<table>
<thead>
<tr>
<th>Apparatus</th>
<th>USP Type I (Basket)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speed of Rotation</td>
<td>100 rpm</td>
</tr>
<tr>
<td>Medium</td>
<td>pH 1.2 buffer Simulated Gastric Fluid without Enzyme</td>
</tr>
<tr>
<td>Volume</td>
<td>900 mL</td>
</tr>
<tr>
<td>Temperature</td>
<td>37.0°C ± 0.5°C</td>
</tr>
</tbody>
</table>

**Specifications for Memantine HCl**

- 1 hr – NMT 90%; 4 hr – NLT 95% and NMT 98%;
- 8 hr – NLT 99% and NMT 99%; and 12 hr – NLT 99%

**Specifications for Donepezil HCl**

- NLT 90% (Q) of the labeled amount of Donepezil HCl is dissolved in 30 minutes

The “interim” dissolution test(s) and tolerances should be finalized by submitting dissolution data for the first three production size batches. Data should be submitted as a Special
Supplement – Changes Being Effected when there are no revisions to the “interim”
specifications or when the final specifications are tighter than the “interim” specifications. In all
other instances, the information should be submitted in the form of a Prior Approval Supplement.

The RLD upon which you have based your ANDA, Forest’s Namzaric Extended-Release
Capsules, 14 mg/10 mg and 28 mg/10 mg, is subject to periods of patent protection. The
following patents and expiration dates are currently listed in the agency’s publication titled
Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”):

<table>
<thead>
<tr>
<th>U.S. Patent Number</th>
<th>Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>8,039,009 (the ‘009 patent)*</td>
<td>September 24, 2029</td>
</tr>
<tr>
<td>8,058,291 (the ‘291 patent)</td>
<td>December 5, 2029</td>
</tr>
<tr>
<td>8,168,209 (the ‘209 patent)*</td>
<td>May 22, 2026</td>
</tr>
<tr>
<td>8,173,708 (the ‘708 patent)*</td>
<td>May 22, 2026</td>
</tr>
<tr>
<td>8,283,379 (the ‘379 patent)*</td>
<td>May 22, 2026</td>
</tr>
<tr>
<td>8,293,794 (the ‘794 patent)</td>
<td>November 22, 2025</td>
</tr>
<tr>
<td>8,329,752 (the ‘752 patent)*</td>
<td>May 22, 2026</td>
</tr>
<tr>
<td>8,338,485 (the ‘485 patent)</td>
<td>November 22, 2025</td>
</tr>
<tr>
<td>8,338,486 (the ‘486 patent)</td>
<td>November 22, 2025</td>
</tr>
<tr>
<td>8,362,085 (the ‘085 patent)*</td>
<td>May 22, 2026</td>
</tr>
<tr>
<td>8,580,858 (the ‘858 patent)</td>
<td>November 22, 2025</td>
</tr>
<tr>
<td>8,598,233 (the ‘233 patent)*</td>
<td>May 22, 2026</td>
</tr>
</tbody>
</table>

*with pediatric exclusivity

Your ANDA contains paragraph IV certifications to each of the patents under section
505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will
not be infringed by your manufacture, use, or sale of Memantine and Donepezil Hydrochloride
Extended-Release Capsules, 14 mg/10 mg and 28 mg/10 mg, under this ANDA. You have
notified the agency that Amneal Pharmaceuticals, LLC (Amneal) complied with the
requirements of section 505(j)(2)(B) of the FD&C Act, and that litigation was initiated against
’233 patents within the statutory 45-day period in the United States District Court for the District
of Delaware [Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd., Allergan USA, Inc.,
and Adams Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals
of New York, LLC, Civil Action No. 1:15-cv-00756-UNA]. You have also notified the agency
that the case has been dismissed.

With respect to 180-day generic drug exclusivity, we note that Amneal was the first ANDA
applicant to submit a substantially complete ANDA with a paragraph IV certification for
Memantine and Donepezil Hydrochloride Extended-Release Capsules, 14 mg/10 mg and

1 The agency notes that the ’009, ’752, ’485, ’486, ’085, ’858 and ’233 patents were submitted to the agency for the
14 mg/10 mg strength of the NDA after submission of your ANDA. Litigation, if any, with respect to these patents
would not create a statutory stay of approval.
28 mg/10 mg. Therefore, with this approval, Amneal is eligible for 180-days of generic drug exclusivity for Memantine and Donepezil Hydrochloride Extended-Release Capsules, 14 mg/10 mg and 28 mg/10 mg. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, will begin to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA informing the agency of the date of commercial marketing.

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of
failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

Carol A. Holquist, RPh
Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research